Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1898 2
1928 2
1929 1
1930 1
1933 1
1934 2
1935 1
1936 1
1946 1
1949 1
1950 1
1952 2
1953 3
1954 2
1955 2
1962 2
1963 1
1964 1
1965 1
1966 1
1967 4
1968 5
1969 2
1970 9
1971 5
1972 8
1973 6
1974 5
1975 6
1976 1
1977 5
1978 3
1979 2
1980 6
1981 8
1982 5
1983 4
1984 6
1985 1
1986 2
1987 3
1988 5
1989 10
1990 4
1991 7
1992 5
1993 7
1994 5
1995 9
1996 16
1997 8
1998 16
1999 10
2000 9
2001 18
2002 15
2003 25
2004 18
2005 24
2006 21
2007 21
2008 22
2009 20
2010 50
2011 46
2012 54
2013 81
2014 77
2015 79
2016 68
2017 82
2018 78
2019 104
2020 131
2021 128
2022 117
2023 123
2024 124
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,628 results

Results by year

Filters applied: . Clear all
Page 1
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial.
Othman J, Wilhelm-Benartzi C, Dillon R, Knapper S, Freeman SD, Batten LM, Canham J, Hinson EL, Wych J, Betteridge S, Villiers W, Kleeman M, Gilkes A, Potter N, Overgaard UM, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Dennis M, Russell NH. Othman J, et al. Among authors: arnold c. Blood Adv. 2023 Aug 22;7(16):4539-4549. doi: 10.1182/bloodadvances.2023010276. Blood Adv. 2023. PMID: 37171402 Free PMC article. Clinical Trial.
Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman SD, Gilkes A, Thomas I, Johnson S, Canham J, Cavenagh J, Kottaridis P, Arnold C, Ommen HB, Overgaard UM, Dennis M, Burnett A, Wilhelm-Benartzi C, Dillon R, Russell NH. Othman J, et al. Among authors: arnold c. Blood. 2024 May 9;143(19):1931-1936. doi: 10.1182/blood.2023023096. Blood. 2024. PMID: 38364112
Dual domestications and origin of traits in grapevine evolution.
Dong Y, Duan S, Xia Q, Liang Z, Dong X, Margaryan K, Musayev M, Goryslavets S, Zdunić G, Bert PF, Lacombe T, Maul E, Nick P, Bitskinashvili K, Bisztray GD, Drori E, De Lorenzis G, Cunha J, Popescu CF, Arroyo-Garcia R, Arnold C, Ergül A, Zhu Y, Ma C, Wang S, Liu S, Tang L, Wang C, Li D, Pan Y, Li J, Yang L, Li X, Xiang G, Yang Z, Chen B, Dai Z, Wang Y, Arakelyan A, Kuliyev V, Spotar G, Girollet N, Delrot S, Ollat N, This P, Marchal C, Sarah G, Laucou V, Bacilieri R, Röckel F, Guan P, Jung A, Riemann M, Ujmajuridze L, Zakalashvili T, Maghradze D, Höhn M, Jahnke G, Kiss E, Deák T, Rahimi O, Hübner S, Grassi F, Mercati F, Sunseri F, Eiras-Dias J, Dumitru AM, Carrasco D, Rodriguez-Izquierdo A, Muñoz G, Uysal T, Özer C, Kazan K, Xu M, Wang Y, Zhu S, Lu J, Zhao M, Wang L, Jiu S, Zhang Y, Sun L, Yang H, Weiss E, Wang S, Zhu Y, Li S, Sheng J, Chen W. Dong Y, et al. Among authors: arnold c. Science. 2023 Mar 3;379(6635):892-901. doi: 10.1126/science.add8655. Epub 2023 Mar 2. Science. 2023. PMID: 36862793
Effects of a physical activity and endometriosis-based education program delivered by videoconference on endometriosis symptoms: the CRESCENDO program (inCRease physical Exercise and Sport to Combat ENDOmetriosis) protocol study.
Escriva-Boulley G, Philip CA, Warembourg S, Lenotre L, Flore P, Faure P, Michy T, Letouzey V, Arnold C, Piluso C, Chalmel L, Kacem R, Blum GF, Detayrac R, Trocmé C, Brigaud I, Herbach U, Branche P, Faller E, Chalabaev A. Escriva-Boulley G, et al. Among authors: arnold c. Trials. 2023 Nov 27;24(1):759. doi: 10.1186/s13063-023-07792-1. Trials. 2023. PMID: 38012776 Free PMC article.
Discovery of Potent, Orally Bioavailable, Tricyclic NLRP3 Inhibitors.
Velcicky J, Janser P, Gommermann N, Brenneisen S, Ilic S, Vangrevelinghe E, Stiefl N, Boettcher A, Arnold C, Malinverni C, Dawson J, Murgasova R, Desrayaud S, Beltz K, Hinniger A, Dekker C, Farady CJ, Mackay A. Velcicky J, et al. Among authors: arnold c. J Med Chem. 2024 Jan 25;67(2):1544-1562. doi: 10.1021/acs.jmedchem.3c02098. Epub 2024 Jan 4. J Med Chem. 2024. PMID: 38175811
Response to Karadag.
Mainz JG, Michl R, Arnold C. Mainz JG, et al. Among authors: arnold c. J Cyst Fibros. 2014 Sep;13(5):602-3. doi: 10.1016/j.jcf.2014.07.005. Epub 2014 Jul 28. J Cyst Fibros. 2014. PMID: 25081561 Free article. No abstract available.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. Among authors: arnold c. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
Pathology in Practice.
Schlemmer SN, Fratzke AP, Ploeg RJ, Whitfield-Cargile C, Arnold C, Rodrigues-Hoffmann A, Older CE, Jeffery U. Schlemmer SN, et al. Among authors: arnold c. J Am Vet Med Assoc. 2021 Feb 15;258(4):379-382. doi: 10.2460/javma.258.4.379. J Am Vet Med Assoc. 2021. PMID: 33539213 Free article. No abstract available.
1,628 results